Trial Profile
A Phase I Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of RN564 In Women With Osteopenia And In Healthy Men.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs RN 564 (Primary)
- Indications Metabolic bone diseases; Osteoporosis
- Focus Adverse reactions
- 21 Jun 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 21 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Dec 2011 Planned End Date changed from 1 Mar 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.